Description from the EGA: " This is a prospective, single arm phase IIa trial in which patients with early breast cancer will receive pre-operatively two doses of denosumab 120mg subcutaneously one week apart (maximum 12 days) followed by surgery. Tumor, normal breast tissue and blood samples will be collected at baseline and at surgery. Post-operative treatment will be at the discretion of the investigator.Primary...
Breast NeoplasmsDenosumabImmunohistochemistryKi-67 AntigenRANK Ligand
- Access Rights
- Application Required